In this Research Rundown, we will discuss a 2022 study that focuses on how Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1a Pathway.
- The Abstract of this study states the following:
Hyperbaric oxygen therapy (HBOT) has been suggested as a potential adjunctive therapy for Parkinson’s disease (PD).
- The Conclusion of the study states the following:
The effects of HBOT in MPTP-treated mice might come from promoting mitochondrial biogenesis, decreasing apoptotic signaling and attenuating inflammatory mediators in the midbrain, suggesting its potential benefits in PD treatment.
- Our host, di Girolamo likes this study and recommends you review it since it’s a newer study and it focuses on a debilitating, progressive neurodegenerative disease that affects motor function in approximately 1% of the population 60+ years old.
- This is an animal study study using MPTP-Treated mice.
- HBOT was found to —
- Attenuate apoptosis of midbrain tissue in MPTP-treated mice
- Improve motor activity and grip strength in the MPTP-treated mice.
- Reduced substantia nigra dopaminergic neuronal loss in MPTP-treated mice
- Inhibit neuroinflammation in the brain of MPTP-treated mice
- Promote mitochondrial biogenesis through the SIRT-1/PGC-1a pathway in MPTP-treated mice
- This study shows that Hyperbaric Oxygen Therapy should certainly be considered for someone who is struggling with Parkinson’s Disease.
Read “Hyperbaric Oxygen Therapy Improves Parkinson’s Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1a Pathway”